ArticleFrontiers in neurology
Serum albumin-to-creatinine ratio as a novel and cost-effective biomarker for silent cerebral infarction: a retrospective cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Silent cerebral infarction (SCI) is a common but underrecognized condition characterized by asymptomatic cerebral lesions detected via magnetic resonance imaging (MRI). While traditional vascular risk factors contribute to its pathogenesis, novel biomarkers may enhance risk stratification. The serum albumin to creatinine ratio (sACR) reflects nutritional status and renal function-two factors closely linked to vascular health. This study aimed to investigate the association between sACR and the presence of SCI, as well as its potential prognostic value for long-term outcomes. Methods: We retrospectively analyzed 272 consecutive patients who visited the neurology outpatient clinic and underwent brain MRI for any reason, provided they met the study's inclusion criteria. Patients with a history of cerebrovascular disease or other exclusion criteria were not included. Baseline demographic and laboratory data, including sACR, were collected. SCI was identified using standardized imaging criteria. Adverse outcomes, including cerebrovascular events and atrial fibrillation/flutter, were assessed over a median follow-up period of 37 months. Results: Patients with SCI had significantly 24 lower sACR levels compared to those without SCI. In multivariable logistic regression analysis, each 1-point decrease in sACR was independently associated with a 1.790-fold increase in the odds of SCI (95% CI: 1.384-2.315, Conclusion: Lower sACR levels are independently associated with the presence of SCI. While the association between sACR and long-term outcomes requires further investigation, sACR may serve as a cost-effective biomarker for assessing subclinical cerebrovascular risk. Future prospective studies are needed to validate these findings and clarify the clinical utility of sACR-guided risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.